Showing results (301-310 of 311) with videos related to
Sort By:
Pageof 32
Journal of Animal Science|January 9, 2015
Definition, willingness-to-pay, and ranking of quality attributes of U.S. pork as defined by importers in Asia and MexicoR G L Murphy, S T Howard, D R Woerner, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2009
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-upM Colleoni, Z Sun, G Martinelli, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyM D Green, H Koelbl, J Baselga, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrinM A Rosenthal, B Kavar, J S Hill, et al.Blood|November 1, 1996
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activationC J O'Malley, J E Rasko, R L Basser, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade gliomaK Clarke, R L Basser, C Underhill, et al.The Journal of Infectious Diseases|June 1, 1996
Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in CambodiaA P Hopperus Buma, P P van Thiel, H O Lobel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factorR L Basser, L B To, C G Begley, et al.British Journal of Cancer|November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerJ Bernhard, D Zahrieh, J J Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-upR L Basser, L B To, J P Collins, et al.Pageof 32